- Home
- INCY vs ONON Comparison
INCY vs ONON Comparison
Compare INCY & ONON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INCY | ONON |
|---|---|---|
| Founded | 1991 | 2010 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Shoe Manufacturing |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.0B | 12.0B |
| IPO Year | 1994 | 2021 |
Fundamental Metrics
Financial Performance| Metric | INCY | ONON |
|---|---|---|
| Price | $96.36 | $34.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 21 | 20 |
| Target Price | ★ $103.52 | $60.15 |
| AVG Volume (30 Days) | 1.3M | ★ 5.2M |
| Earning Date | 04-28-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 4173.33 | N/A |
| EPS | ★ 1.47 | N/A |
| Revenue | ★ $3,394,635,000.00 | N/A |
| Revenue This Year | $10.44 | $19.58 |
| Revenue Next Year | $10.99 | $19.98 |
| P/E Ratio | $65.22 | ★ $56.05 |
| Revenue Growth | ★ 13.67 | N/A |
| 52 Week Low | $57.77 | $31.41 |
| 52 Week High | $112.29 | $61.29 |
Technical Indicators
Market Signals| Indicator | INCY | ONON |
|---|---|---|
| Relative Strength Index (RSI) | 52.19 | 41.22 |
| Support Level | $93.54 | $34.38 |
| Resistance Level | $108.79 | $44.10 |
| Average True Range (ATR) | 3.13 | 1.21 |
| MACD | 0.10 | 0.15 |
| Stochastic Oscillator | 40.54 | 5.90 |
Price Performance
Historical ComparisonAbout INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About ONON On Holding AG
Founded in Switzerland in 2010, sportswear firm On Holding generates 93% of its sales from athletic shoes. The brand is best known for its running shoes and its distinctive CloudTec soles. On also produces athletic apparel (6% of sales) and accessories (1%). The firm's merchandise is available in more than 80 countries and is sold through both wholesale (58% of sales) and company-owned channels (42%). In 2025, On generated 58% of its sales in North America, 25% in Europe, the Middle East, and Africa, and 17% in the Asia-Pacific region.